Belpointe Asset Management LLC Galapagos Nv Transaction History

Belpointe Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$37.44 - $46.51 $224 - $279	6 New	6 $0
Q4 2018 Mar 06, 2019	SELL	$87.81 - $110.65 $393,388 - $495,712	-4,480 Closed	0 $0
Q3 2018 Nov 23, 2018	BUY	$90.63 - $120.22 $1,268 - $1,683	14 Added 0.31%	4,480 $504,000
Q2 2018 Aug 06, 2018	SELL	$88.4 - $105.34 $29,879 - $35,604	-338 Reduced 7.04%	4,466 $412,000
Q1 2018 Aug 06, 2018	BUY	$94.51 - $120.23 $203,480 - $258,855	2,153 Added 81.21%	4,804 $479,000
Q4 2017 Feb 15, 2018	SELL	$84.48 - $104.02 $9,377 - $11,546	-111 Reduced 4.02%	2,651 $249,000
Q3 2017 Nov 16, 2017	BUY	$73.17 - $103.47 $202,095 - $285,784	2,762	2,762 $281,000

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.9B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Belpointe Asset Management LLC with notifications on news.